ConductScience.org, home

Paper36765883

In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib.

Feijtel D and 10 others. Cancers (Basel), 2023. Cited by 16 papers, by iCite.

Cite this record

ConductScience Library. In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib. Papers, record 36765883. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36765883

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
16
iCite
Relative citation ratio, by iCite
1.75
iCite
Revised in PubMed
2023-02-13
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Feijtel DDanny
2Reuvers TGAThom G Ahttps://orcid.org/0000-0003-3989-3312
3van Tuyll-van Serooskerken CChristine
4de Ridder CMACorrina M A
5Stuurman DCDebra C
6de Blois EErik
7Verkaik NSNicole S
8de Bruijn PPeter
9Koolen SLWStijn L W
10de Jong MMarion
11Nonnekens JJuliehttps://orcid.org/0000-0002-9644-7522

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
2016Daniel den Hoed FoundationPubMed

Source PubMed

Download CSV of grants

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127415012ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.Br J Cancer2016https://conductscience.org/library/papers/27415012PubMed
231015566Pharmacological boost of DNA damage response and repair by enhanced biogenesis of DNA damage response RNAs.Sci Rep2019https://conductscience.org/library/papers/31015566PubMed
3509403Transplantation of azaserine-induced carcinomas of pancreas in rats.Cancer Lett1979https://conductscience.org/library/papers/509403PubMed
424959847Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes.PLoS One2014https://conductscience.org/library/papers/24959847PubMed
522202153Actinium-225 in targeted alpha-particle therapeutic applications.Curr Radiopharm2011https://conductscience.org/library/papers/22202153PubMed
620852858Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy.Eur J Nucl Med Mol Imaging2011https://conductscience.org/library/papers/20852858PubMed
732576907Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP.Sci Rep2020https://conductscience.org/library/papers/32576907PubMed
835294740Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.Endocr Pathol2022https://conductscience.org/library/papers/35294740PubMed
928076709Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.N Engl J Med2017https://conductscience.org/library/papers/28076709PubMed
1026596723Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.Eur J Nucl Med Mol Imaging2016https://conductscience.org/library/papers/26596723PubMed
111662924Identification and characterisation in vitro of cells with a non-SCLC cell-like phenotype derived from a continuous SCLC cell line.Anticancer Res1991https://conductscience.org/library/papers/1662924PubMed
1228331954Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.Eur J Nucl Med Mol Imaging2017https://conductscience.org/library/papers/28331954PubMed
1317051156Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.Nature2006https://conductscience.org/library/papers/17051156PubMed
1415285875Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948.Cancer Biother Radiopharm2004https://conductscience.org/library/papers/15285875PubMed
1523103855Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.Cancer Discov2013https://conductscience.org/library/papers/23103855PubMed
1632101125Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward.Curr Top Med Chem2020https://conductscience.org/library/papers/32101125PubMed
1711585290[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.Eur J Nucl Med2001https://conductscience.org/library/papers/11585290PubMed
1829872498Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor.Oncotarget2018https://conductscience.org/library/papers/29872498PubMed
1933355125The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment.Sci Adv2020https://conductscience.org/library/papers/33355125PubMed
2021973238Slow-cycling therapy-resistant cancer cells.Stem Cells Dev2012https://conductscience.org/library/papers/21973238PubMed

See all 30 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.

PMIDTitleJournalYearIn PapersSource
42539504Cellular responses to targeted radionuclide therapy: rethinking radiobiology under continuous low dose rates.Front Oncol2026https://conductscience.org/library/papers/42539504PubMed
42487019Deciphering the phenotypic responses to 177Lu-based radioligand therapy to identify efficacious combinations.Eur J Nucl Med Mol Imaging2026https://conductscience.org/library/papers/42487019PubMed
42439911Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.Clin Cancer Res2026https://conductscience.org/library/papers/42439911PubMed
42228304PARP Inhibitors as Radiosensitizers: Current Evidence and Future Directions.Curr Oncol Rep2026https://conductscience.org/library/papers/42228304PubMed
41367875PARP inhibitors as radiosensitizers: a comprehensive review of preclinical evidence and clinical applications.Front Oncol2025https://conductscience.org/library/papers/41367875PubMed
40000461A mathematical model for the investigation of combined treatment of radiopharmaceutical therapy and PARP inhibitors.Eur J Nucl Med Mol Imaging2025https://conductscience.org/library/papers/40000461PubMed
39682120Characterization of Somatostatin Receptor 2 Gene Expression and Immune Landscape in Sinonasal Malignancies.Cancers (Basel)2024https://conductscience.org/library/papers/39682120PubMed
39136880Enhancing [177Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics.EJNMMI Res2024https://conductscience.org/library/papers/39136880PubMed
39023784Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer.Eur J Nucl Med Mol Imaging2024https://conductscience.org/library/papers/39023784PubMed
38948517Evaluation of a blood miRNA/mRNA signature to follow-up Lu-PRRT therapy for G1/G2 intestinal neuroendocrine tumors.Front Endocrinol (Lausanne)2024https://conductscience.org/library/papers/38948517PubMed
38773983Actinium-225 targeted alpha particle therapy for prostate cancer.Theranostics2024https://conductscience.org/library/papers/38773983PubMed
37351169DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo.Theranostics2023https://conductscience.org/library/papers/37351169PubMed
37190261Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.Cancers (Basel)2023https://conductscience.org/library/papers/37190261PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABCB15243PubTator's text mininghttps://conductscience.org/library/genes/5243NCBI Gene
PARP1142PubTator's text mininghttps://conductscience.org/library/genes/142NCBI Gene
SSTR26752PubTator's text mininghttps://conductscience.org/library/genes/6752NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36765883

GET https://conductscience.org/api/papers/v1/36765883/references?page=2